Bradley Herring Sells 4,645 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) CFO Bradley Herring sold 4,645 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $52,860.10. Following the sale, the chief financial officer now directly owns 324,689 shares in the company, valued at approximately $3,694,960.82. This trade represents a 1.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Bradley Herring also recently made the following trade(s):

• On Wednesday, March 5th, Bradley Herring sold 4,645 shares of Enfusion stock. The shares were sold at an average price of $11.38, for a total transaction of $52,860.10.
• On Monday, March 3rd, Bradley Herring sold 1,533 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total transaction of $17,598.84.
• On Tuesday, January 7th, Bradley Herring sold 4,134 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $41,877.42.
• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The shares were sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Stock Performance

ENFN traded up $0.04 during midday trading on Tuesday, reaching $11.15. 780,007 shares of the company were exchanged, compared to its average volume of 1,156,687. Enfusion, Inc. has a one year low of $7.83 and a one year high of $11.80. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 278.69, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The company's fifty day moving average price is $10.99 and its 200 day moving average price is $9.92.

Remove Ads

Enfusion (NYSE:ENFN - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The business had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. As a group, sell-side analysts anticipate that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enfusion

Hedge funds have recently made changes to their positions in the business. Azora Capital LP grew its position in Enfusion by 3,255.9% during the fourth quarter. Azora Capital LP now owns 1,000,967 shares of the company's stock valued at $10,310,000 after buying an additional 971,140 shares during the period. Silvercrest Asset Management Group LLC bought a new position in shares of Enfusion during the 4th quarter valued at approximately $4,300,000. TenCore Partners LP purchased a new stake in shares of Enfusion during the 3rd quarter worth approximately $3,938,000. EVR Research LP bought a new stake in shares of Enfusion in the 4th quarter worth approximately $4,120,000. Finally, New York State Common Retirement Fund lifted its stake in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company's stock valued at $19,848,000 after purchasing an additional 370,498 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ENFN has been the subject of several recent analyst reports. Stifel Nicolaus increased their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler increased their price target on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.